Pharvaris (NASDAQ:PHVS) Trading 4.3% Higher – Still a Buy?

Pharvaris (NASDAQ:PHVS)’s stock price traded up 4.3% during trading on Thursday . The stock traded as high as $16.65 and last traded at $16.70. 13,304 shares traded hands during trading, a decline of 81% from the average session volume of 71,180 shares. The stock had previously closed at $16.01.

Analyst Upgrades and Downgrades

Separately, JMP Securities boosted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Performance

The firm has a market cap of $883.70 million, a PE ratio of -6.10 and a beta of -3.02. The stock’s 50 day simple moving average is $17.20 and its 200 day simple moving average is $19.15.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris in the 3rd quarter valued at $57,000. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after purchasing an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at $64,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 3rd quarter valued at $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris in the 4th quarter valued at $111,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.